Pioglitazone Exposure Reduced the Risk of All-Cause Mortality in Insulin-Treated Patients with Type 2 Diabetes Mellitus

doi:10.1210/clinem/dgz026

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/24865

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24865

Title:	Pioglitazone Exposure Reduced the Risk of All-Cause Mortality in Insulin-Treated Patients with Type 2 Diabetes Mellitus
Authors:	Yen, FS;Wang, HC;Pan, CW;Wei, JCC;Hsu, CC;Hwu, CM
Keywords:	type 2 diabetes mellitus;insulin;pioglitazone;therapeutics;mortality
Date:	2020
Issue Date:	2022-08-09T08:09:16Z (UTC)
Publisher:	ENDOCRINE SOC
ISSN:	0021-972X
Abstract:	Context: The long-term safety and benefit of pioglitazone use in combination with insulin are still uncertain. Objective: This study compared the risks of all-cause mortality and major cardiovascular (CV) events between pioglitazone users and nonusers receiving insulin therapy. Design, Setting and Patients: We conducted a 13-year retrospective cohort study by using data from the population-based National Health Insurance Research Database in Taiwan. A total of 20 376 patients with type 2 diabetes mellitus (T2DM) receiving insulin therapy were enrolled during 2000 to 2012. Overall, the incidence rates of all-cause mortality and CV events were compared between 2579 pioglitazone users and 2579 matched nonusers. Results: After adjustment for age, sex, comorbidities, Diabetes Complications Severity Index scores, and drugs used, mortality rates were 30.26 and 15.02 per 1000 person-years for pioglitazone nonusers and users, respectively. The adjusted hazard ratio (aHR) of mortality was 0.47 (95% confidence interval [CI]: 0.38-0.58, P < 0.001) for pioglitazone users compared with nonusers. The aHRs of CV and non-CV deaths were 0.78 (95% CI: 0.51-1.19) and 0.50 (95% CI: 0.38-0.66), respectively. The aHRs of hospitalized coronary artery disease, hospitalized stroke, and incident heart failure were not significantly different between pioglitazone users and nonusers. Conclusions: This nationwide cohort study demonstrated that pioglitazone use reduced the risks of all-cause mortality and non-CV death for patients with T2DM undergoing insulin therapy.
URI:	http://dx.doi.org/10.1210/clinem/dgz026 https://www.webofscience.com/wos/woscc/full-record/WOS:000525870500040 https://ir.csmu.edu.tw:8080/handle/310902500/24865
Relation:	JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM ,2020 ,v105 ,issue 3 E401-E409
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	190	View/Open

Loading...